Table 1. Patient demographics and clinical information for samples analyzed by RNA-Seq: Resolution group.
Patient Code | Sex | Age at infection | Ethnicity | rs12979860 IFNL4 genotype | HCV genotype | Testing interval (days)a | Estimated days post-infection | ALT (U/L) | AST (U/L) | HCV viremia | |
---|---|---|---|---|---|---|---|---|---|---|---|
R1 | F | 23 | Indigenousb | CC | NDc | 32 | |||||
Pre-infection | -196 | 29 | 33 | - | |||||||
Early acute | 16 | 199 | 80 | + | |||||||
Late acute | 105 | 42 | 61 | + | |||||||
Follow up | 503 | 31 | 57 | - | |||||||
R2 | M | 44 | Caucasian | CC | 1a | 65 | |||||
Pre-infection | -114 | 23 | 34 | - | |||||||
Early acute | 33 | 25 | 36 | + | |||||||
Follow up | 340 | 28 | 38 | - | |||||||
R3 | M | 24 | Caucasian | CC | 3a | 71 | |||||
Pre-infection | -35 | 29 | 37 | - | |||||||
Early acute | 48 | 458 | 334 | + | |||||||
Late acute | 126 | 18 | 26 | - | |||||||
Follow up | 392 | 21 | 40 | - | |||||||
R4 | M | 25 | Caucasian | CC | 1 | 84 | |||||
Pre-infection | -42 | 24 | 37 | - | |||||||
Early acute | 42 | 2076 | 1335 | + | |||||||
Late acute | 138 | 18 | 30 | - | |||||||
Follow up | 409 | 23 | 37 | - | |||||||
R5 | F | 38 | Eastern European | CC | 3a | 84 | |||||
Pre-infection | -131 | 33 | 25 | - | |||||||
Early acute | 42 | 618 | 807 | + | |||||||
Late acute | 108 | 25 | 34 | + | |||||||
Follow up | 197 | 19 | 28 | - | |||||||
R6 | M | 47 | Caucasian | CT | 1a | 91 | |||||
Pre-infection | -45 | 20 | 31 | - | |||||||
Early acute | 68 | 449 | 208 | + | |||||||
Late acute | 130 | 37 | 39 | + | |||||||
Follow up | 179 | 23 | 36 | - |
a The interval (in days) between the last negative and first positive HCV qualitative RNA test available on record. Values do not necessarily coincide with the availability of research samples or research visits
b The term Indigenous respectfully refers to the First Nations, Inuit, and Métis Peoples of Canada
c ND: Not Done